| 30.06. | BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis.. |  |
| 30.06. | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 30.06. | Novartis livre des indications sur le tislélizumab en oncologie |  |
| 30.06. | BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3.. | |
| 30.06. | BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti.. | |
| 30.06. | BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti.. | |
| 27.06. | BeiGene Grants Share Options, Restricted Share Units | |
| 27.06. | Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd... | |
| 24.06. | Asian ADRs Climb Higher in Friday Trading | |
| 23.06. | BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for .. | |
| 22.06. | INSIDER SELL : Beigene | |
| 22.06. | INSIDER SELL : Beigene | |
| 22.06. | BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote.. | |
| 22.06. | Beigene, Ltd. Announces Executive Changes | |
| 21.06. | European ADRs Rise Sharply in Tuesday Trading | |
| 21.06. | SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Tuesday | |
| 21.06. | BeiGene Says China Regulators Accept Supplemental Biologics License Application for Ant.. | |
| 21.06. | BeiGene Announces Acceptance of Supplemental Biologics License Application in China for.. | |
| 21.06. | Beigene Announces Acceptance of Supplemental Biologics License Application in China for.. | |
| 15.06. | Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-JUN-20.. | |
| 15.06. | Certain Restricted Share Units of BeiGene, Ltd. are subject to a Lock-Up Agreement Endi.. | |
| 15.06. | Certain A Shares of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-JUN-2.. | |
| 14.06. | BEIGENE : Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at .. | |
| 14.06. | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 14.06. | TRANSCRIPT : BeiGene, Ltd. Presents at Goldman Sachs 43rd Annual Global Healthcare Confere.. | |
| 14.06. | FDA Extends PDUFA Goal Date for BeiGene Drug to January 2023; Shares Slip 5.67% | |
| 13.06. | SECTOR UPDATE : Health Care Stocks Slip Premarket Monday | |
| 13.06. | BeiGene's Lymphoma Treatment Approved in Kuwait, Bahrain and Qatar | |
| 13.06. | BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets | |
| 13.06. | Ministry of Health in Kuwait Approves Beigene, Ltd.'s BRUKINSA™ (Zanubrutinib) in .. | |
| 13.06. | BeiGene Says US FDA Extends Fee Act for Supplementary New Drug Application for Brukinsa | |
| 13.06. | BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen.. | |
| 13.06. | Beigene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen.. | |
| 10.06. | Asian ADRs Move Sharply Lower in Friday Trading | |
| 10.06. | SECTOR UPDATE : Health Care Stocks Lean Lower Pre-Bell Friday | |
| 10.06. | BeiGene Secures China's Approval for Tislelizumab Treatment for Nasopharyngeal Cancer; .. | |
| 10.06. | BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at.. | |
| 10.06. | China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer | |
| 10.06. | BeiGene, Ltd. Announces NMPA Grants its Anti-PD-1 Antibody Tislelizumab Approval for Fi.. | |
| 10.06. | BeiGene Gets China OK of Tislelizumab in Nasopharyngeal Cancer | |
| 08.06. | BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | |
| 27.05. | BEIGENE : Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and G.. | |
| 27.05. | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 26.05. | BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and .. | |
| 24.05. | Asian ADRs Move Lower in Tuesday Trading | |
| 17.05. | BeiGene to Open Regional Office in Switzerland | |
| 17.05. | BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi.. | |
| 17.05. | BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland | |
| 12.05. | BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato.. | |
| 11.05. | Asian ADRs Move Higher in Wednesday Trading | |
| 10.05. | Asian ADRs Climb Higher in Tuesday Trading | |
| 09.05. | INSIDER SELL : BeiGene | |
| 09.05. | BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results
.. | |
| 05.05. | BeiGene Swings to Q1 Net Loss as Revenue Declines | |
| 05.05. | Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M | |
| 05.05. | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | |
| 05.05. | BeiGene Reports First Quarter 2022 Financial Results | |
| 05.05. | BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 04.05. | BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute.. | |
| 04.05. | BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P.. | |
| 04.05. | Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patien.. | |
| 29.04. | BeiGene Breaks Ground on Flagship US Facility in New Jersey; Shares Climb | |
| 29.04. | BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes.. | |
| 29.04. | Beigene Breaks Ground on New Manufacturing and Clinical R&D Center At the Princeton Wes.. | |
| 29.04. | BEIGENE : Financial Information - Form 8-K | |
| 28.04. | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | |
| 28.04. | BeiGene's Brukinsa Secures Uruguay's Approval For Lymphoma, Waldenstrom's Macroglobulin.. | |
| 28.04. | BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, .. | |
| 28.04. | Beigene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, .. | |
| 27.04. | BeiGene, Ltd. Announces Global Phase 3 Trial of PD-1 Inhibitor, Tislelizumab, in Combin.. | |
| 27.04. | BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual.. | |
| 27.04. | BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual.. | |
| 27.04. | NOVARTIS : résultats d'une étude pour le tislelizumab | |
| 27.04. | Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che.. | |
| 27.04. | BeiGene Phase 3 Trial for Tislelizumab Meets Primary Endpoint | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
